Symptom-based management of the idiopathic interstitial pneumonia

Respirology

Volumn 21, Issue 8, 2016, Pages 1357-1365

  Garibaldi, Brian T ^a   Danoff, Sonye K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dyspnoea; interstitial lung disease; palliative care; pulmonary fibrosis; pulmonary rehabilitation

Indexed keywords

BENZONATATE; CORTICOSTEROID; OPIATE; SILDENAFIL;

ANXIETY; CLINICAL FEATURE; COUGHING; DEPRESSION; DISEASE ASSOCIATION; DYSPNEA; FATIGUE; HOSPICE CARE; HUMAN; INCIDENCE; INTERSTITIAL PNEUMONIA; NONINVASIVE VENTILATION; OXYGEN THERAPY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; SYMPTOM; PATIENT ACUITY; PROCEDURES; PSYCHOLOGY; SELF CARE; SYMPTOM ASSESSMENT; TERMINAL CARE;

HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; PATIENT ACUITY; PATIENT CARE MANAGEMENT; SELF-MANAGEMENT; SYMPTOM ASSESSMENT; TERMINAL CARE;

EID: 84944411159     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12649     Document Type: Review

References (80)

1. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733–748.
2. Lee JS, McLaughlin S, Collard HR. Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr. Opin. Pulm. Med. 2011; 17: 348–354.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083–2092.
4. Danoff S, Schonhoft E. Role of support measures and palliative care. Curr. Opin. Pulm. Med. 2014; 19: 480–484.
5. Swigris JJ, Stewart AL, Gould MK, Wilson S. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual. Life Outcomes 2005; 3: 61.
6. Gilbert CR, Smith CM. Advanced parenchymal lung disease: quality of life and palliative care. Mt. Sinai J. Med. 2009; 76: 63–70.
7. Swigris JJ, Wilson SR, Green KE, Sprunger DB, Brown KK, Wamboldt FS. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual. Life Outcomes 2010; 8: 1–9.
8. Lanken PN, Terry PB, Delisser HM, Fahy BF, Hansen-Flaschen J, Heffner JE, Levy M, Mularski RA, Osborne ML, Prendergast TJ et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am. J. Respir. Crit. Care Med. 2008; 177: 912–927.
9. Wuyts WA, Peccatori FA, Russell AM. Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models. Eur. Respir. Rev. 2014; 23: 231–238.
10. Schwartzstein R, Adams L. Dyspnea. In: Mason RJ, Broaddus VC, Martin T, King T, Schraufnagel D, Murray JF, Nadel JA (eds) Murray and Nadel's Textbook of Respiratory Medicine. Elsevier, Philadelphia, 2010; 613–627.
11. Dyspnea. Am. J. Respir. Crit. Care Med. 1999; 159: 321–340.
12. Bajwah S, Higginson IJ, Ross JR, Wells AU, Birring SS, Patel A, Riley J. Specialist palliative care is more than drugs: a retrospective study of ILD patients. Lung 2012; 190: 215–220.
13. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 157: 199–203.
14. Collard HR, Pantilat SZ. Dyspnea in interstitial lung disease. Curr. Opin. Support. Palliat. Care 2008; 2: 100–104.
15. Vries JD, Kessels BLJ, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur. Respir. J. 2001; 17: 954–961.
16. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Watanabe F, Nishimura K. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir. Med. 2005; 99: 408–414.
17. Manali ED, Stathopoulos GT, Kollintza A, Kalomenidis I, Emili JM, Sotiropoulou C, Daniil Z, Roussos C, Papiris SA. The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis. Respir. Med. 2008; 102: 586–592.
18. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538–542.
19. Ryerson CJ, Collard HR, Pantilat SZ. Management of dyspnea in interstitial lung disease. Curr. Opin. Support. Palliat. Care 2010; 4: 69–75.
20. Comstock G, Tockman M, Helsing KJ, Hennesy KM. Standardized respiratory questionnaires: comparison of the old with the new. Am. Rev. Respir. Dis. 1979; 110: 45–53.
21. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751–758.
22. Wilson R. A comparison of the visual analogue scale and modified BORG scale for the measurement of dyspnoea during exercise. Clin. Sci. 1989; 76: 277–282.
23. Jones P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992; 145: 1321–1327.
24. Guyatt G, Berman L, Townsend M, Pugsley S, Chambers L. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773–778.
25. Campbell EJM, Howell JBL. The sensation of breathlessness. Br. Med. Bull. 1963; 19: 36–40.
26. O'Donnell DE, Ora J, Webb KA, Laveneziana P, Jensen D. Mechanisms of activity-related dyspnea in pulmonary diseases. Respir. Physiol. Neurobiol. 2009; 167: 116–132.
27. Undem BJ, Nassenstein C. Airway nerves and dyspnea associated with inflammatory airway disease. Respir. Physiol. Neurobiol. 2009; 167: 36–44.
28. Flume PA, Eldridge FL, Edwards LJ, Houser LM. The Fowler breathholding study revisited: continuous rating of respiratory sensation. Respir. Physiol. 1994; 95: 53–66.
29. Belman MJ, Brooks LR, Ross DJ, Mohsenifar Z. Variability of breathlessness measurement in patients with chronic obstructive pulmonary disease. Chest 1991; 99: 566–571.
30. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y et al. Efficacy and safety of Nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071–2082.
31. Richella R, Spathis A, Booth S. Correlates between basic science and therapeutic interventions: the theory and the practice. Curr. Opin. Support. Palliat. Care 2014; 8: 200–207.
32. Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342: 13–14.
33. Nocturnal Oxygen Therapy Trials Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann. Intern. Med. 1980; 93: 391–398.
34. Swinburn CR, Mould H, Stone TN, Corris PA, Gibson GJ. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. Am. Rev. Respir. Dis. 1991; 143: 913–915.
35. Visca D, Montgomery A, de Lauretis A, Sestini P, Soteriou H, Maher TM, Wells AU, Renzoni EA. Ambulatory oxygen in interstitial lung disease. Eur. Respir. J. 2011; 38: 987–990.
36. Frank RC, Hicks S, Duck AM, Spencer L, Leonard CT, Barnett E. Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? Eur. Respir. J. 2012; 40: 269–270.
37. Tomioka H, Imanaka K, Hashimoto K, Iwasaki H. Health-related quality of life in patients with idiopathic pulmonary fibrosis—cross-sectional and longitudinal study. Intern. Med. 2007; 46: 1533–1542.
38. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2013; 188: e13–64.
39. Jastrzebski D, Gumola A, Gawlik R, Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J. Physiol. Pharmacol. 2006; 57: 139–148.
40. Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, Cayou C, Shariat C, Collard HR. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009; 135: 442–447.
41. Kozu R, Senjyu H, Jenkins SC, Mukae H, Sakamoto N, Kohno S. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration 2011; 81: 196–205.
42. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63: 549–554.
43. Weil JV, McCullough RE, Kline JS, Sodal IE. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N. Engl. J. Med. 1975; 292: 1103–1106.
44. Mahler DA. Opioids for refractory dyspnea. Expert Rev. Respir. Med. 2013; 7: 123–135.
45. Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 2000; 66: 2221–2231.
46. Jennings AL, Davies AN, Higgins JPT, Gibbs JSR, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939–944.
47. Allen S, Raut S, Woollard J, Vassallo M. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat. Med. 2005; 19: 128–130.
48. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N. Engl. J. Med. 2010; 363: 620–628.
49. Ryerson CJ, Donesky D, Pantilat SZ, Collard HR. Dyspnea in idiopathic pulmonary fibrosis: a systematic review. J. Pain Symptom Manage. 2012; 43: 771–782.
50. Anand A, Srivastava N, Barwad P, Ramakrishnan S, Roy A, Bhargava B. Dyspnea in Eisenmenger syndrome and its amelioration by sildenafil: role of J receptors. Int. J. Cardiol. 2014; 174: 574–578.
51. Gifford A. Noninvasive ventilation as a palliative measure. Curr. Opin. Support. Palliat. Care 2014; 8: 218–224.
52. Moderno EV, Yamaguti WP, Schettino GP, Kairalla RA, Martins MA, Carvalho CR. Effects of proportional assisted ventilation on exercise performance in idiopathic pulmonary fibrosis patients. Respir. Med. 2010; 104: 134–141.
53. Canning BJ, Chang AB, Bolser DC, Smith JA, Mazzone SB, McGarvey L. Anatomy and neurophysiology of coughing: chest guideline and expert panel report. Chest 2014; 46: 1633–1648.
54. Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011; 16: 969–975.
55. Madison M, Irwin R. Chronic cough in adults with interstitial lung disease. Curr. Opin. Pulm. Med. 2005; 11: 412–416.
56. French CT, Irwin RS, Fletcher KE, Adams TM. Evaluation of a cough-specific quality-of-life questionnaire. Chest 2002; 121: 1123–1131.
57. Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, Danoff SK, Lechtzin N. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann. Intern. Med. 2012; 157: 398–406.
58. Irwin RS, Boulet LP, Cloutier MM, Fuller R, Gold PM, Hoffstein V, Ing AJ, McCool FD, O'Byrne P, Poe RH et al. Managing cough as a defense mechanism and as a symptom: a consensus panel report of the American College of Chest Physicians. Chest 1998; 114: 133S–181.
59. Bolser DC. Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 238S–249.
60. Krajinik M, Jassem E, Sobanski P. Opioid receptor bronchial tree: current science. Curr. Opin. Support. Palliat. Care 2014; 8: 191–199.
61. Doona M, Walsh D. Benzonatate for opioid-resistant cough in advanced cancer. Palliat. Med. 1998; 12: 55–58.
62. Dicpinigaitis PV, Gayle YE, Solomon G, Gilbert RD. Inhibition of cough-reflex sensitivity by benzonatate and guaifenesin in acute viral cough. Respir. Med. 2009; 103: 902–906.
63. Hope-Gill BDM, Hilldrup S, Davies C, Newton RP, Harrison NK. A study of the cough reflex in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 995–1002.
64. Horton MR, Danoff SK, Lechtzin N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax 2008; 63: 749.
65. Okazaki A, Ohkura N, Fujimura M, Katayama N, Kasahara K. Effects of pirfenidone on increased cough reflex sensitivity in guinea pigs. Pulm. Pharmacol. Ther. 2013; 26: 603–608.
66. Swigris JJ, Fairclough DL, Morrison M, Make B, Kozora E, Brown KK, Wamboldt FS. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir. Care 2011; 56: 783–789.
67. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Watanabe F, Arizono S. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest 2005; 127: 2028–2033.
68. Breukink SO, Strijbos JH, Koorn M, Koëter GH, Breslin EH, van der Schans CP. Relationship between subjective fatigue and physiological variables in patients with chronic obstructive pulmonary disease. Respir. Med. 1998; 92: 676–682.
69. Watanabe F, Taniguchi H, Sakamoto K, Kondoh Y, Kimura T, Kataoka K, Ogawa T, Arizono S, Nishiyama O, Hasegawa Y. Quadriceps weakness contributes to exercise capacity in nonspecific interstitial pneumonia. Respir. Med. 2013; 107: 622–628.
70. Spruit MA, Janssen DJ, Franssen FM, Wouters EF. Rehabilitation and palliative care in lung fibrosis. Respirology 2009; 14: 781–787.
71. Holland AE, Hill CJ, Glaspole I, Goh N, McDonald CF. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir. Med. 2012; 106: 429–435.
72. Huppmann P, Sczepanski B, Boensch M, Winterkamp S, Schönheit-Kenn U, Neurohr C, Behr J, Kenn K. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur. Respir. J. 2013; 42: 444–453.
73. Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011; 139: 609–616.
74. Ryerson CJ, Arean PA, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology 2012; 17: 525–532.
75. Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients. Chron. Respir. Dis. 2011; 8: 225–231.
76. Lindell KO, Olshansky E, Song MK, Zullo TG, Gibson KF, Kaminski N, Hoffman LA. Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. Heart Lung 2010; 39: 304–313.
77. Bajwah S, Koffman J, Higginson IJ, Ross JR, Wells AU, Birring SS, Riley J. I wish I knew more—the end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: views of patients, carers and health professionals. BMJ Support. Palliat. Care 2012; 3: 84–90.
78. Higginson IJ, Sen-Gupta GJA. Place of care in advanced cancer: a qualitative systematic literature review of patient preferences. J. Palliat. Med. 2000; 3: 287–300.
79. Lindell KO, Liang Z, Hoffman LA, Rosenzweig MQ, Saul MI, Pilewski JM, Gibson KF, Kaminski N. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest 2015; 147: 423–429.
80. Brown AW, Fischer CP, Shlobin OA, Buhr RG, Ahmad S, Weir NA, Nathan SD. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest 2015; 147: 173–179.